CDKN2A/p16 is inactivated in most melanoma cell lines

Cancer Research

Volumn 57, Issue 21, 1997, Pages 4868-4875

  Castellano, Marina ^a   Pollock, Pamela M ^a   Walters, Marilyn K ^a   Sparrow, Louise E ^a   Down, Louise M ^a   Gabrielli, Brian G ^a   Parsons, Peter G ^a   Hayward, Nicholas K ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MICROSATELLITE DNA; PROTEIN P16;

ARTICLE; CANCER SUSCEPTIBILITY; CHROMOSOME 9P; CHROMOSOME ABERRATION; DELETION MUTANT; FRAMESHIFT MUTATION; GENE MAPPING; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MELANOMA; NORTHERN BLOTTING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RNA TRANSCRIPTION; ZYGOSITY;

BLOTTING, WESTERN; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE DELETION; GENES, P16; HUMANS; MELANOMA; NEOPLASM PROTEINS; SEQUENCE DELETION; TUMOR CELLS, CULTURED;

EID: 0030728259     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Cannon-Albright, L. A., Goldgar, D. E., Meyer, L. J., Lewis, C. M., Anderson, D. E., Fountain, J. W., Hegi, M. E., Wiseman, R. W., Petty, E. M., Bale, A. E., Olopade, O. I., Diaz, M. O., Kwiatkowski, D. J., Piepkorn, M. W., Zone, J. J., and Skolnick, M. H. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science (Washington DC), 258: 1148-1152, 1992.
2. Nancarrow, D., Mann, G., Holland, E., Walker, G., Beaton, S., Walters, M., Luxford, C., Palmer, J., Donald, J., Weber, J., Fountain, J., Kefford, R., and Hayward, N. Confirmation of chromosome 9p linkage to melanoma. Am. J. Hum. Genet., 53: 936-942, 1993.
3. Goldstein, A., Dracopoli, N., Engelstein, M., Fraser, M., Clark, W. H., Jr., and Tucker, M. Linkage of cutaneous melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am. J. Hum. Genet., 54: 489-496, 1994.
4. Gruis, N., Sandkuijl, L. A., van der Velden, P. A., Bergman, W. and Frants, R. R. CDKN2A explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res., 5: 169-177, 1995.
5. Kamb, A., Shattuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N. A., Ding, W., Hussey, C., Tran, T., Miki, Y., Weaver-Feldhaus, J., McClure, M., Aitken, J. F., Anderson, D. E., Bergman, W., Frants, R., Goldgar, D. E., Green, A., MacLennan, R., Martin, N. G., Meyer, L. J., Youl, P., and Zone, J. J. Analysis of the p16 gene (CDKN2A) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat. Genet., 8: 22-26, 1994.
6. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753-756, 1994.
7. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
8. Foulkes, W., Flanders, T. Y., Pollock, P. M., and Hayward, N. K. CDKN2A and cancer. Mol. Med., 3: 5-20, 1996.
9. Pollock, P. M., Pearson, J. V., and Hayward, N. K. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer, 15: 77-88, 1996.
10. Ohta, M., Nagai, H., Shimizu, M., Rasio, D., Berd, D., Mastrangelo, M., Singh, A. D., Shields, J. A., Shields, C. L., Croce, C. M., and Huebner, K. Rarity of somatic and germline mutations in the cyclin-dependent kinase 4 inhibitor gene, CDK41, in melanoma. Cancer Res., 54: 5269-5272, 1994.
11. Liu, Q., Neuhausen, S., McClure, M., Frye, C., Weaver-Feldhaus, J., Gruis, N. A., Eddington, K., Allalunis-Turner, M. J., Skolnick, M. H., Fujimura, F. K., and Kamb, A. CDKN2A (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene, 10: 1061-1067, 1995.
12. Luca, M., Xie, S., Gutman, M., Huang, S., and Bar-Eli, M. Abnormalities in the CDKN2A (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis. Oncogene, 11: 1399-1402, 1995.
13. Pollock, P. M., Yu, F., Qiu, L., Parsons, P. G., and Hayward, N. K. Evidence of UV induction of CDKN2 mutations in melanoma cell lines. Oncogene, 11: 663-668, 1995.
14. Flores, J., Walker, G. J., Glendening, J. M., Haluska, F. G., Castresana, J. S., Rubio, M. P., Pastorfide, G. C., Boyer, L. S., Kao, W. H., Bulyk, M. L., Barnhill, R. L., Hayward, N. K., Housman, D. E., and Fountain, J. W. Loss of p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers in sporadic melanoma. Cancer Res., 56: 5023-5032, 1996.
15. Gruis, N., Weaver-Feldhaus, J. M., Liu, Q., Frye, C., Eeles, R., Orlow, I., Lacombe, L., Ponce-Castaneda, V., Lianes, P., Latres, E., Skolnick, M., Cordon-Cardo, C., and Kamb, A. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am. J. Pathol., 146: 1199-1206, 1995.
16. Healy, E., Sikkink, S., and Rees, J. L. Infrequent mutation of p16INK4 in sporadic melanoma. J. Invest. Dermatol., 107: 318-321, 1996.
17. Maelandsmo, G., Florenes, V. A., Hovig, E., Oyjord T., Engebraaten, O., Holm, R., Borresen, A-L., and Fodstad, O. Involvement of pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Br. J. Cancer, 73: 909-916, 1996.
18. Ohta, M., Berd, D., Shimizu, M., Nagai, H., Cotticelli, M-G., Mastrangelo, M., Shields, J. A., Shields, C. L., Croce, C. M., and Huebner, K. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. Int. J. Cancer, 65: 762-767, 1996.
19. Platz, A., Ringborg, U., Lagerlof, B., Lundqvist, E., Sevigny, P., and Inganas, M. Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma. Br. J. Cancer, 73: 344-348, 1996.
20. Hayward, N. K. The current situation with regard to human melanoma and genetic inferences. Curr. Opin. Oncol., 8: 136-142, 1996.
21. Elledge, S., and Harper, J. W. Cdk inhibitors: on the threshold of checkpoints and development. Curr. Opin. Cell Biol., 6: 847-852, 1994.
22. Grana, X., and Reddy, E. P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene, 11: 211-219, 1995.
23. Sherr, C. J., and Roberts, J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.
24. Ranade, K., Hussussian, C. J., Sikorski, R. S., Varmus, H. E., Goldstein, A. M., Tucker, M. A., Serrano, M., Hannon, G. J., Beach, D., and Dracopoli, N. C. Mutations associated with familial melanoma impair p16ink4 function. Nat. Genet., 10: 114-116, 1995.
25. Koh, J., Enders, G. H., Dynlacht, B. D., and Harlow, E. Tumor-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature (Lond.), 375: 506-510, 1995.
26. Yang, R., Gombart, A. F., Serrano, M., and Koeffler, H. P. Mutational effects on the p16Ink4a tumor suppressor protein. Cancer Res., 55: 2503-2506, 1995.
27. Walker, G. J., Nancarrow, D. J., Walters, M. K., Palmer, J. M., Weber, J. L., and Hayward, N. K. Linkage analysis in familial melanoma kindreds to markers on chromosome 6p. Int. J. Cancer, 59: 771-775, 1994.
28. Mao, L., Merlo, A., Bedi, G., Shapiro, G. L. Edwards, C. D., Rollins, B. J., and Sidransky, D. A novel p16INK4A transcript. Cancer Res., 55: 2995-2997, 1995.
29. Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Jr., Tucker, M. A., and Dracopoli, N. C. Germline p16 mutations in familial melanoma. Nat. Genet., 8: 15-21, 1994.
30. Wechsler, D. S., Hawkins, A. L., Li, X., Wang Jabs, E., Griffin, C. A., and Dang, C. V. Localization of the human Mxi1 transcription factor gene (MX11) to chromosome 10q24-q25. Genomics, 21: 669-672, 1994.
31. Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieh, E., De Plaen, E., Hankeln, T., Meyer zum Buschenfelde, K., and Beach, D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (Washington DC), 269: 1281-1284, 1995.
32. Cairns, P., Polascik, T. J., Eby, Y., Tokino, K., Califano, J., Merlo, A., Mao, L., Herath, J., Jenkins, R., Westra, W., Rutter, J. L., Buckler, A., Gabrielson, E., Tockman, M., Cho, K. R., Hedrick, L., Steven Bova, G., Isaacs, W., Koch, W., and Schwab, D. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat. Genet., 11: 210-212, 1995.
33. Wang, Y., and Becker, D. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system. Oncogene, 12: 1069-1075, 1996.
34. Cayuela, J-M., Madani, A., Sanhes, L., Stern, M-H., and Sigaux F. Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood, 87: 2180-2186, 1996.
35. Stone, S., Jiang, P., Dayananth, P., Tavtigian, S. V., Katcher, H., Parry, D., Peters, G., and Kamb, A. Complex structure and regulation of the p16(MTS1) locus. Cancer Res., 55: 2988-2994, 1995.
36. Reymond, A., and Brent, R. p16 proteins from melanoma-prone families are deficient in binding to Cdk4. Oncogene, 11: 1173-1178, 1995.
37. Parry, D., and Peters G. Temperature sensitive mutants of p16/CDKN2 associated with familial melanoma. Mol. Cell. Biol., 16: 3844-3852, 1996.
38. Kozak, M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell, 44: 283-292, 1986.
39. Kozak, M. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res., 15: 8125-8148, 1987.
40. Lilischkis, R., Sarcevic, B., Kennedy, C., Walters, A., and Sutherland, R. L. Cancer-associated missense and deletion mutations impair p16INK4 CDK inhibitory activity. Int. J. Cancer, 66: 249-254, 1996.
41. Shapiro, G. I., Park, J. E., Edwards, C. D., Mao, L., Merlo, A., Sidransky, D., Ewen, M. E., and Rollins, B. J. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res., 55: 6200-6209, 1995.
42. Nakagawa, K., Conrad, N. K., Williams, J. P., Johnson, B. E., and Kelley, M. J. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. Oncogene, 11: 1843-1851, 1995.
43. Gonzalez-Zulueta, M., Bender, C. M., Yang, A. S., Nguyen, T., Beart, R. W., Van Tornout, J. M., and Jones, P. A. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res., 55: 4531-4535, 1995.
44. Herman, J., Merlo, A., Mao, L., Lapidus, R. G., Issa J-P., Davidson, N. E., Sidransky, D., and Baylin, S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.
45. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
46. Calabro', V., Strazzullo, M., La Mantia, G., Fedele, M., Paulin, C., Fusco, A., and Lania, L. Status and expression of the p16INK4 gene in human thyroid tumors and thyroid-tumor cell lines. Int. J. Cancer, 67: 29-34, 1996.
47. Goldstein, A. M., Fraser, M. C., Struewing, J. P., Hussussian, C. J., Ranade, K., Zametkin, D. P., Fontaine, L. S., Organic, S. M., Dracopoli, N. C., Clark, W. H., and Tucker, M. A. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N. Engl. J. Med., 333: 970-974, 1995.
48. Okamoto, A., Demetrick, D. J., Spillare, E. A., Hagiwara, K., Hussain, S. P., Bennett, W. P., Forrester, K., Gerwin, B., Serrano, M., Beach, D. H., and Harris, C. C. Mutations and altered expression of p16 INK4 in human cancer. Proc. Natl. Acad. Sci. USA, 91: 11045-11049, 1994.
49. Musgrove, E., Lilischkis, R., Cornish, A. L., Lee, C. S. L., Setlur, V., Seshadri, R., and Sutherland, R. L. Expression of the cyclin-dependent kinase inhibitor p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer. Int. J. Cancer, 63: 584-591, 1995.
50. Yeager, T., Stadler, W., Belair, C., Puthenveettil, J., Olopade, O., and Reznikoff, C. Increased p16 levels correlate with pRB alterations in human urothelial cells. Cancer Res., 55: 493-497, 1995.
51. Naumann, M., Savitskaia, N., Eilert, C., Schramm, A., Kalthoff, H., and Schmiegel, W. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology, 110: 1215-1224, 1996.
52. Srivenugopal, K., and Ali-Osman, F. Deletions and rearrangements inactivate the p16INK4 gene in human glioma cells. Oncogene, 12: 2029-2034, 1996.
53. Reed, J., Loganzo, F., Jr., Shea, C. R., Walker, G. J., Flores, J. F., Glendening, J. M., Bogdany, J. K., Shiel, M. J., Haluska, F. G., Fountain, J. W., and Albino, A. P. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res., 55: 2713-2718, 1995.
54. Bartkova, J., Lukas, J., Guldberg, P., Alsner, J., Kirkin, A. F., Zeuthen, J., and Bartec, J. The p16-cyclin D/Cdk4-Rb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res., 56: 5475-5483, 1996.
55. Walker, G. J., Flores, J. F., Glendening, J. M., You, E., Markl, I. D. C., and Fountain, J. W. Virtually 100% of melanoma cell lines harbor alterations within the p16/p15 genes or one of their downstream targets. Am. J. Hum. Genet., 59 (Suppl.): A6, 1996.
56. Hartmann, A., Blaszyk, H., Cunningham, J. S., McGovern, R. M., Schroeder, J. S., Helander, S. D., Pittelkow, M. R., Sommer, S. S., and Kovach, J. S. Overexpression and mutations of p53 in metastatic malignant melanomas. Int. J. Cancer, 67: 313-317, 1996.
57. van Elsas, A., Zerp, S. F., van der Flier, S., Kruse, K. M., Aarnoudse, C., Hayward, N. K., Ruiter, D. J., and Schrier, P. I. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am. J. Pathol., 149: 883-893, 1996.